Professor Richard Scolyer recognised in The Pathologist's 2020 Power List.
3 August 2020
The Pathologist reports on research, innovations, personalities, and policies that shape pathology. Each year The Pathologist celebrates 100 inspirational and influential professionals in laboratory medicine.
Professor Scolyer has been recognised in the Big Breakthroughs category, due to his cutting-edge research discoveries that have changed clinical and pathology practice worldwide. He is a leader in determining mechanisms of enhanced response versus resistance to drugs in development, such as immunotherapies – data that underpins the design of current clinical trials.
A world leader in melanoma pathology, Professor Scolyer provides a clinical consultation service for the diagnosis of difficult pigmented lesions, receiving over 2,000 cases from around the world each year.
“My biggest influence has been the Melanoma Institute Australia Research Database that was set up by the late Gerry Milton 60 years ago,” Professor Scolyer says. “This is now the largest melanoma patient database in the world, with over 50,000 patients, and is a major international resource that has provided me with many opportunities to perform important research that correlates pathological and clinical features with patient outcome data in large cohorts.
“Whatever you do, make sure you enjoy the process – because it’s through passion and fulfilment that you will have success and achieve things,”
And Professor Scolyer’s biggest wish? “That people of all ages, but especially young people, were more vigilant in protecting themselves from the sun. UV exposure leading to sunburn is the single biggest risk factor for developing melanoma, which claims one Australian life every five hours.”
See the full 2020 Power List here: https://thepathologist.com/power-list/2020
Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Sharing our knowledge of melanoma on the global stage
As leaders in the field of melanoma, clinicians and researchers from MIA will be sharing their knowledge at the virtual 10th World Congress of Melanoma.
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
An inspiring WA Melanoma Community Forum
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
Family of 8-year-old with melanoma calls on all Australians to step up to help save lives
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
Rethinking skin surveillance for high-risk melanoma patients
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Australia's oldest melanoma survivor steps up to save lives on his 105th birthday
Melanoma research saved Bert's life at 101 and now he wants to give back.
Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.
Exploring our own clinical questions through MIA's new trials initiative
MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials.
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Young researchers receive boost to develop innovative treatment for melanoma
Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.
Launch of Melanoma March 2021
Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.
Olivia Vivian announced as MIA ambassador
Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad.
Melanoma breakthrough - neoadjuvant treatment saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Melanoma breakthrough - neoadjuvant therapy saving lives.
Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.
A message to all Australians from melanoma patient Stuart Taylor
Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate.
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.
It's 'Game On Mole' this summer!
All Australians are urged to join the fight against melanoma this summer.